Hypha Labs (FUNI) 10-Q 18 Aug 23 2023 Q3 Quarterly report Financial data

Cover

Cover - shares	9 Months Ended
	Jun. 30, 2023	Aug. 18, 2023
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Jun. 30, 2023
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2023
Current Fiscal Year End Date	--09-30
Entity File Number	000-54239
Entity Registrant Name	Digipath, Inc.
Entity Central Index Key	0001502966
Entity Tax Identification Number	27-3601979
Entity Incorporation, State or Country Code	NV
Entity Address, Address Line One	6450 Cameron St
Entity Address, Address Line Two	Suite 113
Entity Address, City or Town	Las Vegas
Entity Address, State or Province	NV
Entity Address, Postal Zip Code	89118
City Area Code	(702)
Local Phone Number	527-2060
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Elected Not To Use the Extended Transition Period	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		87,096,820

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Jun. 30, 2023	Sep. 30, 2022
Current assets:
Cash	$ 325,587	$ 56,168
Note receivable		100,000
Other current assets	10,010	12,739
Assets held for sale - current	353,375	393,197
Total current assets	688,972	562,104
Fixed assets, net		55,000
Assets held for sale – long term	606,588	722,784
Total non-current assets	606,588	777,784
Total Assets	1,295,560	1,339,888
Current liabilities:
Accounts payable	202,685	215,558
Current maturities of notes payable	665,000	665,000
Liabilities held for sale - current	474,800	529,085
Total current liabilities	3,255,983	2,953,909
Non-current liabilities:
Liabilities held for sale – long term	175,634	310,253
Total non-current liabilities	175,634	795,251
Total Liabilities	3,431,617	3,749,160
Series B convertible preferred stock, $0.001 par value, 1,500,000 shares authorized; 333,600 shares issued and outstanding as of June 30, 2023 and September 30, 2022	333,600	333,600
Stockholders’ Deficit:
Common stock, $0.001 par value, 250,000,000 shares authorized; 87,096,820 and 75,146,820 shares issued and outstanding at June 30, 2023 and September 30, 2022, respectively	87,097	75,147
Common stock payable		71,745
Additional paid-in capital	17,465,264	17,117,958
Accumulated deficit	(20,023,066)	(20,008,771)
Total Stockholders’ Deficit	(2,469,657)	(2,742,872)
Total Liabilities and Stockholders’ Deficit	1,295,560	1,339,888
Series A Convertible Preferred Stock [Member]
Stockholders’ Deficit:
Preferred stock value	1,048	1,048
Series C Convertible Preferred Stock [Member]
Stockholders’ Deficit:
Preferred stock value		1
Nonrelated Party [Member]
Current liabilities:
Accrued expenses – related party	209,520	152,986
Current maturities of convertible notes payable related parties, net of discounts	1,364,158	1,198,469
Non-current liabilities:
Convertible notes payable, net of discounts and current maturities		174,726
Related Party [Member]
Current liabilities:
Accrued expenses – related party	7,813	192,811
Current maturities of convertible notes payable related parties, net of discounts	332,007
Non-current liabilities:
Convertible notes payable, net of discounts and current maturities		$ 310,272

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Jun. 30, 2023	Sep. 30, 2022
Preferred stock, par value	$ 0.001
Preferred stock, shares authorized	10,000,000
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	250,000,000	250,000,000
Common stock, shares issued	87,096,820	75,146,820
Common stock, shares outstanding	87,096,820	75,146,820
Series B Convertible Preferred Stock [Member]
Temporary equity, par value	$ 0.001	$ 0.001
Temporary equity, shares authorized	1,500,000	1,500,000
Temporary equity, shares issued	333,600	333,600
Temporary equity, shares outstanding	333,600	333,600
Series A Convertible Preferred Stock [Member]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	6,000,000	6,000,000
Preferred stock, shares issued	1,047,942	1,047,942
Preferred stock, shares outstanding	1,047,942	1,047,942
Series C Convertible Preferred Stock [Member]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	1,000	1,000
Preferred stock, shares issued	0	1,000
Preferred stock, shares outstanding	0	1,000

Consolidated Statements of Oper

Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Income Statement [Abstract]
Revenues
Cost of sales
Gross profit
Operating expenses:
General and administrative	8,815	35,711	94,013	117,846
Professional fees	86,435	74,201	262,072	624,423
Total operating expenses	95,250	109,912	356,085	742,269
Operating loss	(95,250)	(109,912)	(356,085)	(742,269)
Other income (expense):
Other Expense			(55,000)
Recovery of previously written off receivables	40,000		175,000
Credit Loss		(358,670)		(358,670)
Interest income		12,386		37,061
Interest expense	(97,748)	(67,560)	(277,607)	(204,235)
Total other expense	(57,748)	(413,844)	(157,607)	(525,844)
Net loss from continuing operations	(152,998)	(523,756)	(513,692)	(1,268,113)
Net income (loss) from discontinued operations	446,531	(52,977)	499,397	40,181
Net income (loss)	293,533	(576,733)	(14,295)	(1,227,932)
Preferred deemed dividend				(192,154)
Net income (loss) to common shareholders	$ 293,533	$ (576,733)	$ (14,295)	$ (1,420,086)
Weighted average number of common shares outstanding – basic	84,055,062	75,146,820	82,856,710	73,845,233
Weighted average number of common shares outstanding – fully diluted	84,055,062	75,146,820	82,856,710	73,845,233
Net loss per share from continuing operations – basic	$ 0	$ (0.01)	$ (0.01)	$ (0.02)
Net income (loss) per share from discontinued operations – basic	0.01	0	0.01	0
Net loss per share – basic	0	(0.01)	0	(0.02)
Net loss per share from continuing operations – diluted	0	(0.01)	(0.01)	(0.02)
Net income (loss) per share from discontinued operations – diluted	0.01	0	0.01	0
Net loss per share – diluted	$ 0	$ (0.01)	$ 0	$ (0.02)

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Deficit (Unaudited) - USD ($)	Preferred Stock [Member] Series B Convertible Preferred Stock [Member]	Preferred Stock [Member] Series A Convertible Preferred Stock [Member]	Preferred Stock [Member] Series C Convertible Preferred Stock [Member]	Common Stock [Member]	Stock Payable [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Beginning balance, value at Sep. 30, 2021		$ 1,326		$ 71,230		$ 16,825,765	$ (17,951,653)	$ (1,053,332)
Beginning balance, shares at Sep. 30, 2021		1,325,942		71,230,153
Stock-based compensation						33,457		33,457
Net loss							(277,603)	(277,603)
Common stock issued for services				$ 1,500		51,000		52,500
Common stock issued for services, shares				1,500,000
Series B Preferred shares sold for cash	$ 55,600
Series B Preferred shares sold for cash, shares	55,600
Conversion of Series A Preferred Shares into Series B Preferred	$ 278,000	$ (278)				(85,568)		(85,846)
Conversion of Series A Preferred Shares into Series B Preferred, shares	278,000	(278,000)
Deemed dividend on preferred exchange						(192,154)		(192,154)
Ending balance, value at Dec. 31, 2021	$ 333,600	$ 1,048		$ 72,730		16,632,500	(18,229,256)	(1,522,978)
Ending balance, shares at Dec. 31, 2021	333,600	1,047,942		72,730,153
Beginning balance, value at Sep. 30, 2021		$ 1,326		$ 71,230		16,825,765	(17,951,653)	(1,053,332)
Beginning balance, shares at Sep. 30, 2021		1,325,942		71,230,153
Net loss								(1,227,932)
Ending balance, value at Jun. 30, 2022	$ 333,600	$ 1,048		$ 75,147		16,749,353	(19,179,585)	(2,354,037)
Ending balance, shares at Jun. 30, 2022	333,600	1,047,942		75,146,820
Beginning balance, value at Dec. 31, 2021	$ 333,600	$ 1,048		$ 72,730		16,632,500	(18,229,256)	(1,522,978)
Beginning balance, shares at Dec. 31, 2021	333,600	1,047,942		72,730,153
Net loss							(373,596)	(373,596)
Common Shares issued for settlement of accounts payable				$ 250		7,250		7,500
Common Shares issued for settlement of accounts payable, shares				250,000
Stock-based compensation				$ 2,167		101,297		103,464
Stock-based compensation, shares				2,166,667
Ending balance, value at Mar. 31, 2022	$ 333,600	$ 1,048		$ 75,147		16,741,047	(18,602,852)	(1,785,610)
Ending balance, shares at Mar. 31, 2022	333,600	1,047,942		75,146,820
Net loss							(576,733)	(576,733)
Stock-based compensation						8,306		8,306
Ending balance, value at Jun. 30, 2022	$ 333,600	$ 1,048		$ 75,147		16,749,353	(19,179,585)	(2,354,037)
Ending balance, shares at Jun. 30, 2022	333,600	1,047,942		75,146,820
Beginning balance, value at Sep. 30, 2022	$ 333,600	$ 1,048	$ 1	$ 75,147	71,745	17,117,958	(20,008,771)	(2,742,872)
Beginning balance, shares at Sep. 30, 2022	333,600	1,047,942	1,000	75,146,820
Issuance of common shares to settle stock payable				$ 7,150	(71,745)	64,595
Issuance of common shares to settle stock payable, shares				7,150,000
Warrants issued as debt financing costs						93,938		93,938
Stock-based compensation						8,306		8,306
Net loss							(240,330)	(240,330)
Ending balance, value at Dec. 31, 2022	$ 333,600	$ 1,048	$ 1	$ 82,297		17,284,797	(20,249,101)	(2,880,958)
Ending balance, shares at Dec. 31, 2022	333,600	1,047,942	1,000	82,296,820
Beginning balance, value at Sep. 30, 2022	$ 333,600	$ 1,048	$ 1	$ 75,147	71,745	17,117,958	(20,008,771)	(2,742,872)
Beginning balance, shares at Sep. 30, 2022	333,600	1,047,942	1,000	75,146,820
Net loss								(14,295)
Ending balance, value at Jun. 30, 2023	$ 333,600	$ 1,048		$ 87,097		17,465,264	(20,023,066)	(2,469,657)
Ending balance, shares at Jun. 30, 2023	333,600	1,047,942		87,096,820
Beginning balance, value at Dec. 31, 2022	$ 333,600	$ 1,048	$ 1	$ 82,297		17,284,797	(20,249,101)	(2,880,958)
Beginning balance, shares at Dec. 31, 2022	333,600	1,047,942	1,000	82,296,820
Stock-based compensation						9,204		9,204
Net loss							(67,498)	(67,498)
Repurchased of preferred C stock			$ (1)	$ 0	0	(99)		(100)
Repurchased of preferred C stock, shares			(1,000)	0
Common shares to be issued for compensation					32,120			32,120
Ending balance, value at Mar. 31, 2023	$ 333,600	$ 1,048		$ 82,297	32,120	17,293,902	(20,316,599)	(2,907,232)
Ending balance, shares at Mar. 31, 2023	333,600	1,047,942		82,296,820
Issuance of common shares to settle stock payable				$ 4,400	(32,120)	27,720
Issuance of common shares to settle stock payable, shares				4,400,000
Stock-based compensation						3,482		3,482
Net loss							293,533	293,533
Common stock issued for services				$ 400		2,160		2,560
Common stock issued for services, shares				400,000
Forgiveness of accrued compensation by members of the Board of Directors						138,000		138,000
Ending balance, value at Jun. 30, 2023	$ 333,600	$ 1,048		$ 87,097		$ 17,465,264	$ (20,023,066)	$ (2,469,657)
Ending balance, shares at Jun. 30, 2023	333,600	1,047,942		87,096,820

Consolidated Statements of Cash

Consolidated Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Cash flows from operating activities
Net loss from continuing operations	$ (513,692)	$ (1,268,113)
Adjustments to reconcile net loss to net cash used in operating activities:
Recovery of previously written off receivables	(175,000)
Stock-based compensation	55,672	197,727
Amortization of debt discounts	106,636	58,654
Impairment of fixed assets	55,000
Credit loss		358,670
Decrease (increase) in assets:
Other current assets	2,729	(33,666)
Increase (decrease) in liabilities:
Accounts payable	(12,873)	49,867
Accrued expenses	56,534	192,253
Accrued expenses – related parties	(46,998)
Net cash used in operating activities from continuing operations	(471,992)	(444,608)
Net cash provided by operating activities from discontinued operations	520,843	275,691
Net cash provided by (used in) operating activities	48,851	(168,917)
Cash flows from investing activities
Advance of note receivable		(817,649)
Proceeds from sale of collateralized assets	275,000	175,000
Net cash provided by (used in) investing activities from continuing operations	275,000	(642,649)
Net cash used in investing activities from discontinued operations	(8,971)	(4,246)
Net cash provided by (used in) investing activities	266,029	(646,895)
Cash flows from financing activities
Proceeds from notes payable		390,000
Proceeds from convertible notes		402,765
Payments on convertible notes		(40,000)
Proceeds from sale of preferred stock		55,600
Repurchase of preferred C stock	(100)
Net cash provided by (used in) financing activities from continuing operations	(100)	808,365
Net cash used in financing activities from discontinued operations	(45,361)	(63,252)
Net cash provided by (used in) financing activities	(45,461)	745,113
Net increase (decrease) in cash	269,419	(70,699)
Cash – beginning	56,168	295,932
Cash – ending	325,587	225,233
Supplemental disclosures:
Interest paid	187,449	57,439
Income taxes paid
Non-cash investing and financing activities:
Common stock issued for settlement of stock payable	71,745
Warrants issued for debt financing	93,938
Receipt of assets on deposit	6,076
Forgiveness of related party accrued compensation	138,000
Common stock issued for settlement of accounts payable		7,500
Conversion of Series A preferred into Series B preferred		85,846
Deemed dividend on preferred exchange		$ 192,154

Nature of Business and Signific

Nature of Business and Significant Accounting Policies	9 Months Ended
	Jun. 30, 2023
Accounting Policies [Abstract]
Nature of Business and Significant Accounting Policies	Note 1 – Nature of Business and Significant Accounting Policies Nature of Business Digipath, Inc. was incorporated in Nevada on October 5, 2010. Digipath, Inc. and its subsidiaries (“Digipath,” the “Company,” “we,” “our” or “us”) is a service-oriented independent testing laboratory, data analytics and media firm focused on the developing cannabis and hemp markets, and supports the cannabis industry’s best practices for reliable testing, cannabis education and training. Our mission is to provide pharmaceutical-grade analysis and testing to the cannabis industry, under ISO-17025:2017 guidelines, to ensure consumers and patients know exactly what is in the cannabis they ingest and to help maximize the quality of our clients’ products through research, development, and standardization. Digipath has been operating a cannabis-testing lab in Nevada since 2015. Basis of Presentation The accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”). Intercompany accounts and transactions have been eliminated. The unaudited condensed consolidated financial statements of the Company and the accompanying notes included in this Quarterly Report on Form 10-Q are unaudited. In the opinion of management, all adjustments necessary for a fair presentation of the Condensed Consolidated Financial Statements have been included. Such adjustments are of a normal, recurring nature. The Condensed Consolidated Financial Statements, and the accompanying notes, are prepared in accordance with GAAP and do not contain certain information included in the Company’s Annual Report on Form 10-K for the fiscal year ended September 30, 2022. The interim Condensed Consolidated Financial Statements should be read in conjunction with that Annual Report on Form 10-K. Results for the interim periods presented are not necessarily indicative of the results that might be expected for the entire fiscal year. Principles of Consolidation The accompanying consolidated financial statements include the accounts of the following entities, all of which were under common control and ownership at June 30, 2023: Schedule of Entities Under Common Control and Ownership Jurisdiction of Name of Entity Incorporation Relationship Digipath, Inc. (1) Nevada Parent Digipath Labs, Inc. Nevada Subsidiary Digipath Labs CA, Inc (2) California Subsidiary Digipath Labs S.A.S. (3) Colombia Subsidiary VSSL Enterprises, Ltd. (4) Canada Subsidiary (1) Holding company, which owns each of the wholly-owned subsidiaries. All subsidiaries shown above are wholly-owned by Digipath, Inc., the parent company. (2) Formed during the second fiscal quarter of 2021, but has not yet commenced significant operations. (3) Formed during the first fiscal quarter of 2019, but has not yet commenced significant operations. (4) Acquired on March 11, 2020. The consolidated financial statements herein contain the operations of the wholly-owned subsidiaries listed above. All significant inter-company transactions have been eliminated in the preparation of these financial statements. The parent company and subsidiaries will be collectively referred to herein as the “Company”, “Digipath” or “DIGP”. The Company’s headquarters are located in Las Vegas, Nevada and substantially all of its customers are within the United States. These statements reflect all adjustments, consisting of normal recurring adjustments, which in the opinion of management are necessary for fair presentation of the information contained therein. Correction of an Error Stock-based compensation expenses were reported in the nine months ended June 30, 2022 as $210,449 in error. The error was corrected in the annual 2022 10-K as a component of professional fees. In addition, the Company reported the exchange of Series A Preferred Stock for Series B Stock as an exchange with equal value in error. The effect of the error corrections on the prior periods has been determined to be immaterial, however, the Company has labeled the column headings for the prior periods as “revised.” For the nine months ended June 30, 2022, the financial statements of the line items affected by the revision are as follows: Schedule of Correction of an Error Consolidated Statement of Operations Line items for Q3-2022 effected by the restatement Previously Reported Correction of Error Effect of Discontinued operations Revised Professional Fees $ 635,969 $ (12,722 ) $ 1,176 $ 624,423 Total operating expenses 1,455,757 (12,722 ) (700,766 ) 742,269 Operating loss (701,704 ) 12,722 (53,287 ) (742,269 ) Net loss (1,240,654 ) 12,722 - (1,227,932 ) Deemed Dividend - (192,154 ) - (192,154 ) Net Income (loss) to common shareholders (1,240,654 ) (179,432 ) - (1,420,086 ) Consolidated Statement of Cash Flows Line items for Q3-2022 effected by the restatement Previously Reported Correction of Error Effect of Discontinued operations Revised Net Loss $ (1,240,654 ) $ 12,722 $ (40,181 ) $ (1,268,113 ) Stock-based compensation 210,449 (12,722 ) - 197,727 Non-cash Investing and Financing Activities Conversion of Series A preferred into Series B preferred 278,000 (192,154 ) - 85,846 Deemed dividend on preferred exchange 192,154 - 192,154 Fair Value of Financial Instruments The Company adopted ASC 820, Fair Value Measurements and Disclosures (“ASC 820”). ASC 820 defines fair value, establishes a three-level valuation hierarchy for disclosures of fair value measurement and enhances disclosure requirements for fair value measures. The three levels are defined as follows: - Level 1 inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets. - Level 2 inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial instrument. - Level 3 inputs to valuation methodology are unobservable and significant to the fair measurement. The carrying value of cash, accounts receivable, accounts payables and accrued expenses are estimated by management to approximate fair value primarily due to the short term nature of the instruments. Revenue Recognition The Company recognizes revenue in accordance with ASC 606 — Revenue from Contracts with Customers. Under ASC 606, the Company recognizes revenue from the commercial sales of products, licensing agreements and contracts to perform pilot studies by applying the following steps: (1) identify the contract with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to each performance obligation in the contract; and (5) recognize revenue when each performance obligation is satisfied. Our revenue is primarily generated through our subsidiary, Digipath Labs, Inc. (“Digipath Labs”), which recognizes revenue from the analytical testing of cannabis products for licensed producers and cultivators within the state of Nevada on a determinable fixed fee per test, or panel of tests basis. Revenue from the performance of those services is recognized upon completion of the tests, at which time test results are delivered to the customer, provided collectability of the fee is reasonably assured. We typically require payment within thirty days of the delivery of results. Management estimates an allowance for doubtful accounts based on the aging of its receivables. Discontinued Operations On April 20, 2023, the Company and Digipath Labs entered into an Asset Purchase Agreement (the “Purchase Agreement”) with DPL NV, LLC (“Buyer”), pursuant to which Digipath Labs has agreed to sell substantially all of its assets to Buyer for a cash purchase price of $ 2,300,000 Assets and liabilities of the discontinued operations are aggregated and reported separately as assets and liabilities of discontinued operations in the Consolidated Balance Sheets as of June 30, 2023 and September 30, 2022. The results of discontinued operations are aggregated and presented separately in the Consolidated Statements of Operations as net income from discontinued operations for the periods ended June 30, 2023 and 2022. The cash flows of the discontinued operations are reflected as cash flows of discontinued operations within the Company’s Consolidated Statements of Cash Flows for the periods ended June 30, 2023 and 2022. Amounts presented in discontinued operations have been derived from our consolidated financial statements and accounting records using the historical basis of assets, liabilities, results of operations, and cash flows of Digipath Labs. The discontinued operations exclude general corporate allocations. Stock-Based Compensation The Company accounts for equity instruments issued to employees in accordance with the provisions of ASC 718 Stock Compensation (ASC 718) and Equity-Based Payments to Non-employees pursuant to ASC 2018-07 (ASC 2018-07). All transactions in which the consideration provided in exchange for the purchase of goods or services consists of the issuance of equity instruments are accounted for based on the fair value of the consideration received or the fair value of the equity instrument issued, whichever is more reliably measurable. The measurement date of the fair value of the equity instrument issued is the earlier of the date on which the counterparty’s performance is complete or the date at which a commitment for performance by the counterparty to earn the equity instruments is reached because of sufficiently large disincentives for nonperformance. Income Taxes The Company recognizes deferred tax assets and liabilities based on differences between the financial reporting and tax basis of assets and liabilities using the enacted tax rates and laws that are expected to be in effect when the differences are expected to be recovered. The Company provides a valuation allowance for deferred tax assets for which it does not consider realization of such assets to be more likely than not. Uncertain Tax Positions In accordance with ASC 740, “Income Taxes” (“ASC 740”), the Company recognizes the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be capable of withstanding examination by the taxing authorities based on the technical merits of the position. These standards prescribe a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. These standards also provide guidance on de-recognition, classification, interest and penalties, accounting in interim periods, disclosure, and transition. Various taxing authorities periodically audit the Company’s income tax returns. These audits include questions regarding the Company’s tax filing positions, including the timing and amount of deductions and the allocation of income to various tax jurisdictions. In evaluating the exposures connected with these various tax filing positions, including state and local taxes, the Company records allowances for probable exposures. A number of years may elapse before a particular matter, for which an allowance has been established, is audited and fully resolved. The Company has not yet undergone an examination by any taxing authorities. The assessment of the Company’s tax position relies on the judgment of management to estimate the exposures associated with the Company’s various filing positions. Basic and Diluted Loss Per Share The basic net loss per common share is computed by dividing the net loss by the weighted average number of common shares outstanding. Diluted net loss per common share is computed by dividing the net loss adjusted on an “as if converted” basis, by the weighted average number of common shares outstanding plus potential dilutive securities. For the three and nine months ended June 30, 2023 and 2022, potential dilutive securities of 96,705,198 72,520,865 Reclassifications Certain reclassifications have been made to the prior period financial statements to conform to the current period presentation. These reclassifications had no effect on our previously reported results of operations or accumulated deficit. Recently Issued Accounting Pronouncements There are no recently issued accounting pronouncements that the Company has yet to adopt that are expected to have a material effect on its financial position, results of operations, or cash flows.

Going Concern

Going Concern	9 Months Ended
	Jun. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Going Concern	Note 2 – Going Concern As shown in the accompanying consolidated financial statements, As of June 30, 2023, the Company had negative working capital of $ 2,567,011 20,023,066 325,587 The consolidated financial statements do not include any adjustments that might result from the outcome of any uncertainty as to the Company’s ability to continue as a going concern. These financial statements also do not include any adjustments relating to the recoverability and classification of recorded asset amounts or amounts and classifications of liabilities that might be necessary should the Company be unable to continue as a going concern.

Fair Value of Financial Instrum

Fair Value of Financial Instruments	9 Months Ended
	Jun. 30, 2023
Investments, All Other Investments [Abstract]
Fair Value of Financial Instruments	Note 3 – Fair Value of Financial Instruments Under FASB ASC 820-10-5, fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (an exit price). The standard outlines a valuation framework and creates a fair value hierarchy in order to increase the consistency and comparability of fair value measurements and the related disclosures. Under GAAP, certain assets and liabilities must be measured at fair value, and FASB ASC 820-10-50 details the disclosures that are required for items measured at fair value. The Company has certain financial instruments that must be measured under the new fair value standard. The following schedule summarizes the valuation of financial instruments at fair value on a recurring basis in the balance sheets as of June 30, 2023 and September 30, 2022, respectively: Summary of Financial Instruments at Fair Value on Recurring Basis Level 1 Level 2 Level 3 Fair Value Measurements at June 30, 2023 Level 1 Level 2 Level 3 Assets Cash $ 325,587 $ - $ - Liabilities Notes payable - 665,000 - Convertible notes payable, net of discounts of $ 72,069 - - 1,696,165 Level 1 Level 2 Level 3 Fair Value Measurements at September 30, 2022 Level 1 Level 2 Level 3 Assets Cash $ 56,168 $ - $ - Liabilities Notes payable - 665,000 - Convertible notes payable, net of discounts of $ 84,767 - - 1,683,467 There were no transfers of financial assets or liabilities between Level 1, Level 2 and Level 3 inputs for the nine months ended June 30, 2023.

Related Party Transactions

Related Party Transactions	9 Months Ended
	Jun. 30, 2023
Related Party Transactions [Abstract]
Related Party Transactions	Note 4 – Related Party Transactions During the nine months ended June 30, 2023 the Company incurred compensation expense of $ 45,000 111,437 During the nine months ended June 30, 2023 the Company incurred fees of $ 47,000 30,000 138,000 5,000 As of June 30, 2023, the Company has accrued a total of $ 2,813 During the nine months ended June 30, 2023, the Company granted 3,400,000 1,400,000 24,820 9,860

Note Receivable

Note Receivable	9 Months Ended
	Jun. 30, 2023
Receivables [Abstract]
Note Receivable	Note 5 – Note Receivable On various dates between December 28, 2018 and June 13, 2019, we loaned Northwest Analytical Labs, Inc. a total of $ 95,000 10 On various dates between August 23, 2021 and September 30, 2022, we loaned C3 Labs, Inc. (“C3 Labs”) a total of $ 1,047,649 8 August 23, 2022 64,017 The loans were made in connection with a potential acquisition of a controlling interest in C3 Labs pursuant to a letter of intent. On March 11, 2022, the Company notified the current owners of C3 Labs of its termination of the letter of intent and took possession of the equipment of C3 Labs (“C3 Equipment”). On December 8, 2022, the Company entered into an Asset Purchase Agreement with Invictus Wealth Group (“Invictus”), whereby the Company agreed to sell the C3 Equipment to Invictus for a total purchase price of $ 900,000 275,000 625,000 December 31, 2023 10 100,000 425,000 275,000 100,000 425,000

Fixed Assets

Fixed Assets	9 Months Ended
	Jun. 30, 2023
Property, Plant and Equipment [Abstract]
Fixed Assets	Note 6 – Fixed Assets Fixed assets consist of the following at June 30, 2023 and September 30, 2022: Schedule of Fixed Assets June 30, September 30, As of June 30, September 30, 2023 2022 Lab equipment - 55,000 Fixed assets, gross - 55,000 Less: accumulated depreciation - - Total $ - $ 55,000 During the nine months ended June 30, 2023, the Company recorded impairment expense in the amount of $ 55,000

Notes Payable

Notes Payable	9 Months Ended
	Jun. 30, 2023
Notes Payable [Abstract]
Notes Payable	Note 7 – Notes Payable Notes payable consists of the following at June 30, 2023 and September 30, 2022, respectively: Schedule of Notes Payable June 30, 2023 September 30, 2022 Notes payable - - On September 10, 2021, the Company issued a Secured Promissory note in the principal amount of $ 675,000 12 September 10, 2024 22,419.66 115,000 125,000 $ 665,000 $ 665,000 Total notes payable 665,000 665,000 Less: current maturities (665,000 ) (665,000 ) Notes payable $ - $ - The Company recorded interest expense pursuant to the stated interest rate and closing costs on the notes payable in the amount of $ 59,686 65,785 Notes payable – discontinued operations On December 26, 2019, the Company financed the purchase of $ 377,124 291,931 5.75 5,622 five-year December 26, 2024 95,987 141,348

Convertible Notes Payable

Convertible Notes Payable	9 Months Ended
	Jun. 30, 2023
Debt Disclosure [Abstract]
Convertible Notes Payable	Note 8 – Convertible Notes Payable Related Party Convertible notes payable consist of the following at June 30, 2023 and September 30, 2022, respectively: Schedule of Related Party Convertible Notes Payable June 30, September 30, 2023 2022 Related party convertible notes payable $ - $ 310,272 On February 10, 2020, the Company completed the sale to an accredited investor of a 9% Secured Convertible Promissory Note in the principal amount of $ 350,000 August 10, 2022 9 0.15 0.03 50,000 400,000 50,000 1,666,667 0.03 February 11, 2024 4,550,000 43,788 $ 350,000 $ 350,000 Total related party convertible notes payable 350,000 350,000 Less: unamortized debt discounts (17,993 ) (39,728 ) Total convertible debt 332,007 310,272 Less: current maturities (332,007 ) - Related party convertible notes payable $ - $ 310,272 Convertible notes payable consist of the following at June 30, 2023 and September 30, 2022, respectively: Schedule of Convertible Notes Payable June 30, September 30, 2023 2022 Convertible notes payable $ - $ 174,726 On February 11, 2020, the Company completed the sale to an accredited investor of a 9% Secured Convertible Promissory Note in the principal amount of $ 50,000 August 11, 2022 9 0.15 0.03 10,000 60,000 10,000 333,334 0.03 February 11, 2024 650,000 6,989 $ 50,000 $ 50,000 On February 11, 2020, the Company completed the sale to an accredited investor of a 9% Secured Subordinated Convertible Promissory Note in the principal amount of $ 150,000 August 11, 2022 9 0.15 0.03 50,000 200,000 50,000 1,666,667 0.03 February 11, 2024 1,950,000 20,968 150,000 150,000 On September 23, 2019, the Company received proceeds of $ 200,000 8 August 10, 2022 0.11 August 10, 2022 0.03 90,000 3,000,000 0.03 355,469 98,188 February 11, 2024 4,621,105 32,166 355,469 355,469 On November 8, 2018, the Company received proceeds of $ 350,000 8 August 10, 2022 0.14 August 10, 2022 0.03 February 11, 2024 4,550,000 31,671 350,000 350,000 On October 1, 2022, The Company entered into a senior secured convertible note that carries an 8 February 11, 2024 362,765 0.01 4,715,945 30,102 362,765 362,765 On November 5, 2018, the Company received proceeds of $ 150,000 8 August 10, 2022 0.14 August 10, 2022 0.03 150,000 150,000 Total convertible notes payable 1,418,234 1,418,234 Less: unamortized debt discounts (54,076 ) (45,039 ) Total convertible debt 1,364,158 1,373,195 Less: current maturities (1,364,158 ) (1,198,469 ) Convertible notes payable $ - $ 174,726 In addition, the Company recognized and measured the embedded beneficial conversion feature present in the convertible notes by allocating a portion of the proceeds equal to the intrinsic value of the feature to additional paid-in-capital. The intrinsic value of the feature was calculated on the commitment date using the effective conversion price of the convertible notes. This intrinsic value is limited to the portion of the proceeds allocated to the convertible debt. The aforementioned accounting treatment resulted in a total debt discount equal to $ 93,938 106,636 58,654 72,069 All of the convertible notes limit the maximum number of shares that can be owned by each note holder as a result of the conversions to common stock to 4.99 The Company recorded interest expense pursuant to the stated interest rates on the convertible notes in the amount of $ 111,285 79,796 The Company recognized interest expense for the nine months ended June 30, 2023 and 2022, respectively, as follows: Schedule of Interest Expense June 30, June 30, 2023 2022 Interest on notes payable 59,686 65,785 Amortization of beneficial conversion features 106,636 58,654 Interest on convertible notes 111,285 79,796 Total interest expense $ 277,607 $ 204,235

Stockholders_ Equity

Stockholders’ Equity	9 Months Ended
	Jun. 30, 2023
Equity [Abstract]
Stockholders’ Equity	Note 9 – Stockholders’ Equity Preferred Stock The Company is authorized to issue 10,000,000 0.001 6,000,000 1,500,000 1,000 2,499,000 1,047,942 333,600 no Series A The conversion price is adjustable in the event of stock splits and other adjustments in the Company’s capitalization, and in the event of certain negative actions undertaken by the Company. At the current conversion price, the 1,047,942 5,239,710 No holder is permitted to convert its shares of Series A Preferred if such conversion would cause the holder to beneficially own more than 4.99% of the issued and outstanding common stock of the Company immediately after such conversion, unless waived by such holder by providing at least sixty-five days’ notice. Additional terms of the Series A Preferred and include the following: ● The shares of Series A Preferred are entitled to dividends when, as and if declared by the Board as to the shares of the common stock of the Company into which such Series A Preferred may then be converted, subject to the 4.99 ● Upon the liquidation or dissolution of the Company, or any merger or sale of all or substantially all of the assets, the shares of Series A Preferred are entitled to receive, prior to any distribution to the holders of common stock, 100 ● The Series A Preferred plus all declared but unpaid dividends thereon automatically will be converted into common stock, at the then applicable conversion rate, upon the affirmative vote of the holders of a majority of the outstanding shares of Series A Preferred. ● Each share of Series A Preferred will carry a number of votes equal to the number of shares of common stock into which such Series A Preferred may then be converted, subject to the 4.99 ● Consent of the holders of the outstanding Series A Preferred is required in order for the Company to: (i) amend or change the rights, preferences, privileges or powers of, or the restrictions provided for the benefit of, the Series A Preferred; (ii) authorize, create or issue shares of any class of stock having rights, preferences, privileges or powers superior to the Series A Preferred; (iii) reclassify any outstanding shares into shares having rights, preferences, privileges or powers superior to the Series A Preferred; or (iv) amend the Company’s Articles of Incorporation or Bylaws in a manner that adversely affects the rights of the Series A Preferred. ● Pursuant to the Securities Purchase Agreements, holders of Series A Preferred are entitled to unlimited “piggyback” registration rights on registrations by the Company, subject to pro rata cutback at any underwriter’s discretion. Series C The Series C Preferred were designated on July 20, 2022. The principal feature of the Series C Preferred Stock is that it provides the holder thereof, so long as he or she is an executive officer of the Company, with the ability to vote with the holders of the Company’s common stock on all matters presented to the holders of common stock, whether at a special or annual meeting, by written action in lieu of a meeting or otherwise, on the basis of 200,000 votes for each share of Series C Preferred Stock. 0.10 Additional terms of the Series C Preferred and include the following: ● The shares of Series C Preferred are not entitled to dividends. ● Upon the liquidation or dissolution of the Company, or any merger or sale of all or substantially all of the assets, or upon a change in control whereby a stockholder gains control of 50% or more of the outstanding shares of common stock, the shares of Series C Preferred are entitled to receive, prior to any distribution to the holders of common stock, 100% of the stated value per share of Series C Preferred. ● The shares of Series C Preferred are not entitled to conversion rights. On March 2, 2023, the Company entered into a Preferred Stock Repurchase Agreement with Todd Denkin, the Company’s president, pursuant to which Mr. Denkin surrendered his Series C Preferred back to the Company for the purchase price of $ 100 Common Stock Common stock consists of $ 0.001 250,000,000 87,096,820 During the nine months ended June 30, 2023, the Company issued 7,150,000 71,745 During the nine months ended June 30, 2023, the Company granted 3,400,000 1,400,000 24,820 9,860

Mezzanine Equity

Mezzanine Equity	9 Months Ended
	Jun. 30, 2023
Mezzanine Equity
Mezzanine Equity	Note 10 – Mezzanine Equity Series B The Series B Preferred were designated on December 29, 2021. Each share of Series B Preferred has a Stated Value of $ 1.00 0.04 333,600 8,340,000 No holder is permitted to convert its shares of Series B Preferred if such conversion would cause the holder to beneficially own more than 4.99% of the issued and outstanding common stock of the Company immediately after such conversion, unless waived by such holder by providing at least sixty-five days’ notice. Additional terms of the Series B Preferred and include the following: ● The shares of Series B Preferred are not entitled to dividends, provided that if dividends are paid on the shares of common stock of the Company, the Series B Preferred will be entitled to dividends based on the number shares of common stock which the Series B Preferred may then be converted. ● Upon the liquidation or dissolution of the Company, or any merger or sale of all or substantially all of the assets, or upon a change in control whereby a stockholder gains control of 50% or more of the outstanding shares of common stock, the shares of Series B Preferred are entitled to receive, prior to any distribution to the holders of common stock, 100% of the purchase price per share of Series B Preferred plus all accrued but unpaid dividends. ● Each share of Series B Preferred carries a number of votes equal to the number of shares of common stock into which such Series B Preferred may then be converted. Due to the change in control provision of the Series B Preferred, the Series B Preferred is classified as temporary equity on the balance sheet.

Common Stock Options

Common Stock Options	9 Months Ended
	Jun. 30, 2023
Share-Based Payment Arrangement [Abstract]
Common Stock Options	Note 11 – Common Stock Options Stock Incentive Plan On June 21, 2016, we amended and restated our 2012 Stock Incentive Plan (the “2012 Plan”), which was originally adopted on March 5, 2012, and terminated on March 5, 2022. As amended, the 2012 Plan provides for the issuance of up to 11,500,000 During the nine months ended June 30, 2023, the Company issued to certain employees, options to purchase 2,100,000 10,446 184 0.00497 0.0056 5.75 Amortization of Stock-Based Compensation A total of $ 20,992 66,949 4,643 The following is a summary of information about the stock options outstanding at June 30, 2023. Summary of Common Stock Options Outstanding Shares Underlying Options Outstanding Shares Underlying Options Exercisable Weighted Shares Average Weighted Shares Weighted Range of Underlying Remaining Average Underlying Average Exercise Options Contractual Exercise Options Exercise Prices Outstanding Life Price Exercisable Price $ 0.0056 0.13 8,120,000 5.28 $ 0.052 6,020,000 $ 0.069 The fair value of each option grant is estimated on the date of grant using the Black-Scholes option pricing model with the following weighted-average assumptions used for grants during the nine months ended June 30, 2023: Schedule of Weighted-Average Assumptions Used for Grants June 30, 2023 Average risk-free interest rates 3.88 % Average expected life (in years) 2.90 Volatility 184 % The Black-Scholes option pricing model was developed for use in estimating the fair value of short-term traded options that have no vesting restrictions and are fully transferable. In addition, option valuation models require the input of highly subjective assumptions including expected stock price volatility. Because the Company’s common stock options have characteristics significantly different from those of traded options and because changes in the subjective input assumptions can materially affect the fair value estimate, in management’s opinion the existing models do not necessarily provide a reliable single measure of the fair value of its common stock options. During the nine months ended June 30, 2023, there were no options granted with an exercise price below the fair value of the underlying stock at the grant date. The weighted average fair value of options granted with exercise prices at the current fair value of the underlying stock during the nine months ended June 30, 2023, was approximately $ 0.006 The following is a summary of activity of outstanding common stock options: Schedule of Activity of Outstanding Common Stock Options Weighted Average Number Exercise of Shares Price Balance, September 30, 2022 6,020,000 $ 0.069 Options issued 2,100,000 0.006 Options forfeited - - Balance, June 30, 2023 8,120,000 $ 0.052 Exercisable, June 30, 2023 6,020,000 $ 0.069 As of June 30, 2023, these options in the aggregate had $ 3,150 0 0.007

Common Stock Warrants

Common Stock Warrants	9 Months Ended
	Jun. 30, 2023
Common Stock Warrants
Common Stock Warrants	Note 12 – Common Stock Warrants Warrants to purchase a total of 15,387,050 The following is a summary of information about our warrants to purchase common stock outstanding at June 30, 2023 (including those issued to both investors and service providers). Summary of Common Stock Warrants Outstanding Shares Underlying Shares Underlying Warrants Outstanding Warrants Exercisable Weighted Shares Average Weighted Shares Weighted Range of Underlying Remaining Average Underlying Average Exercise Warrants Contractual Exercise Warrants Exercise Prices Outstanding Life Price Exercisable Price $ 0.0074 0.10 15,387,050 9.01 $ 0.02 15,387,050 $ 0.02 The following is a summary of activity of outstanding common stock warrants: Schedule of Outstanding Common Stock Warrants Activity Weighted Average Number Exercise of Shares Price Balance, September 30, 2022 1,500,000 $ 0.10 Warrants granted 13,887,050 $ 0.007 Warrants expired - - Balance, June 30, 2023 15,387,050 $ 0.016 Exercisable, June 30, 2023 15,387,050 $ 0.016 As of June 30, 2023, these warrants in the aggregate had $ 0 0.007

Discontinued Operations

Discontinued Operations	9 Months Ended
	Jun. 30, 2023
Discontinued Operations and Disposal Groups [Abstract]
Discontinued Operations	Note 13 – Discontinued Operations On April 20, 2023, the Company, and Digipath Labs entered into the Purchase Agreement with DPL NV, LLC (“Buyer”), pursuant to which Digipath Labs has agreed to sell substantially all of its assets to Buyer for a cash purchase price of $ 2,300,000 150,000 The Purchase Agreement includes a number of representations, warrantees, covenants and conditions to closing customary for this type of transaction. In addition, the closing of the transaction is subject to the approval of the Nevada Cannabis Compliance Board (the “CCB”). In the event CCB approval is not obtained by June 30, 2024, or any other condition to closing has not been satisfied by such date, either party may terminate the Purchase Agreement. Pursuant to the Purchase Agreement, the Buyer deposited $ 230,000 The balance sheets of Digipath Labs are summarized below: Schedule of Discontinued Operations Income Statement Balance Sheet and Additional Disclosures June 30, 2023 September 30, 2022 Current assets: Accounts receivable, net $ 302,300 $ 335,085 Deposits 18,675 25,141 Other current assets 32,400 32,971 Total current assets 353,375 393,197 Right-of-use asset 240,602 316,961 Fixed assets, net 365,986 405,823 Total long term assets 606,588 722,784 Total Assets $ 959,963 $ 1,115,981 Current liabilities: Accounts payable $ 241,991 $ 334,909 Accrued expenses 58,439 32,571 Current portion of operating lease liabilities 110,772 100,685 Current maturities of notes payable 63,598 60,920 Total current liabilities 474,800 529,085 Operating lease liabilities 143,245 229,825 Notes payable 32,389 80,428 Total long term liabilities 175,634 310,253 Total Liabilities $ 650,434 $ 839,338 The statements of operations of Digipath Labs combined are summarized below: For the Three Months Ended For the Nine Months Ended June 30, June 30, 2023 2022 2023 2022 Revenues $ 785,224 $ 682,665 $ 2,272,689 $ 1,986,985 Cost of sales 382,655 414,299 1,265,098 1,232,932 Gross profit 402,569 268,366 1,007,591 754,053 Operating expenses: General and administrative 226,466 309,766 731,457 701,942 Professional fees 50,843 6,907 94,302 (1,176 ) Total operating expenses 277,309 316,673 825,759 700,766 Operating income(loss) 125,260 (48,307 ) 181,832 53,287 Other income (expense): Other income 322,798 - 322,798 - Interest expense (1,527 ) (4,670 ) (5,233 ) (13,106 ) Total other income (expense) 321,271 (4,670 ) 317,565 (13,106 ) Net income (loss) $ 446,531 $ (52,977 ) $ 499,397 $ 40,181

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Jun. 30, 2023
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 14 – Commitments and Contingencies Legal Contingencies There are no material pending legal proceedings to which we are a party or to which any of our property is subject, nor are there any such proceedings known to be contemplated by governmental authorities. None of our directors, officers or affiliates is involved in a proceeding adverse to our business or has a material interest adverse to our business.

Nature of Business and Signif_2

Nature of Business and Significant Accounting Policies (Policies)	9 Months Ended
	Jun. 30, 2023
Accounting Policies [Abstract]
Nature of Business	Nature of Business Digipath, Inc. was incorporated in Nevada on October 5, 2010. Digipath, Inc. and its subsidiaries (“Digipath,” the “Company,” “we,” “our” or “us”) is a service-oriented independent testing laboratory, data analytics and media firm focused on the developing cannabis and hemp markets, and supports the cannabis industry’s best practices for reliable testing, cannabis education and training. Our mission is to provide pharmaceutical-grade analysis and testing to the cannabis industry, under ISO-17025:2017 guidelines, to ensure consumers and patients know exactly what is in the cannabis they ingest and to help maximize the quality of our clients’ products through research, development, and standardization. Digipath has been operating a cannabis-testing lab in Nevada since 2015.
Basis of Presentation	Basis of Presentation The accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”). Intercompany accounts and transactions have been eliminated. The unaudited condensed consolidated financial statements of the Company and the accompanying notes included in this Quarterly Report on Form 10-Q are unaudited. In the opinion of management, all adjustments necessary for a fair presentation of the Condensed Consolidated Financial Statements have been included. Such adjustments are of a normal, recurring nature. The Condensed Consolidated Financial Statements, and the accompanying notes, are prepared in accordance with GAAP and do not contain certain information included in the Company’s Annual Report on Form 10-K for the fiscal year ended September 30, 2022. The interim Condensed Consolidated Financial Statements should be read in conjunction with that Annual Report on Form 10-K. Results for the interim periods presented are not necessarily indicative of the results that might be expected for the entire fiscal year.
Principles of Consolidation	Principles of Consolidation The accompanying consolidated financial statements include the accounts of the following entities, all of which were under common control and ownership at June 30, 2023: Schedule of Entities Under Common Control and Ownership Jurisdiction of Name of Entity Incorporation Relationship Digipath, Inc. (1) Nevada Parent Digipath Labs, Inc. Nevada Subsidiary Digipath Labs CA, Inc (2) California Subsidiary Digipath Labs S.A.S. (3) Colombia Subsidiary VSSL Enterprises, Ltd. (4) Canada Subsidiary (1) Holding company, which owns each of the wholly-owned subsidiaries. All subsidiaries shown above are wholly-owned by Digipath, Inc., the parent company. (2) Formed during the second fiscal quarter of 2021, but has not yet commenced significant operations. (3) Formed during the first fiscal quarter of 2019, but has not yet commenced significant operations. (4) Acquired on March 11, 2020. The consolidated financial statements herein contain the operations of the wholly-owned subsidiaries listed above. All significant inter-company transactions have been eliminated in the preparation of these financial statements. The parent company and subsidiaries will be collectively referred to herein as the “Company”, “Digipath” or “DIGP”. The Company’s headquarters are located in Las Vegas, Nevada and substantially all of its customers are within the United States. These statements reflect all adjustments, consisting of normal recurring adjustments, which in the opinion of management are necessary for fair presentation of the information contained therein. Correction of an Error Stock-based compensation expenses were reported in the nine months ended June 30, 2022 as $210,449 in error. The error was corrected in the annual 2022 10-K as a component of professional fees. In addition, the Company reported the exchange of Series A Preferred Stock for Series B Stock as an exchange with equal value in error. The effect of the error corrections on the prior periods has been determined to be immaterial, however, the Company has labeled the column headings for the prior periods as “revised.” For the nine months ended June 30, 2022, the financial statements of the line items affected by the revision are as follows: Schedule of Correction of an Error Consolidated Statement of Operations Line items for Q3-2022 effected by the restatement Previously Reported Correction of Error Effect of Discontinued operations Revised Professional Fees $ 635,969 $ (12,722 ) $ 1,176 $ 624,423 Total operating expenses 1,455,757 (12,722 ) (700,766 ) 742,269 Operating loss (701,704 ) 12,722 (53,287 ) (742,269 ) Net loss (1,240,654 ) 12,722 - (1,227,932 ) Deemed Dividend - (192,154 ) - (192,154 ) Net Income (loss) to common shareholders (1,240,654 ) (179,432 ) - (1,420,086 ) Consolidated Statement of Cash Flows Line items for Q3-2022 effected by the restatement Previously Reported Correction of Error Effect of Discontinued operations Revised Net Loss $ (1,240,654 ) $ 12,722 $ (40,181 ) $ (1,268,113 ) Stock-based compensation 210,449 (12,722 ) - 197,727 Non-cash Investing and Financing Activities Conversion of Series A preferred into Series B preferred 278,000 (192,154 ) - 85,846 Deemed dividend on preferred exchange 192,154 - 192,154
Fair Value of Financial Instruments	Fair Value of Financial Instruments The Company adopted ASC 820, Fair Value Measurements and Disclosures (“ASC 820”). ASC 820 defines fair value, establishes a three-level valuation hierarchy for disclosures of fair value measurement and enhances disclosure requirements for fair value measures. The three levels are defined as follows: - Level 1 inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets. - Level 2 inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial instrument. - Level 3 inputs to valuation methodology are unobservable and significant to the fair measurement. The carrying value of cash, accounts receivable, accounts payables and accrued expenses are estimated by management to approximate fair value primarily due to the short term nature of the instruments.
Revenue Recognition	Revenue Recognition The Company recognizes revenue in accordance with ASC 606 — Revenue from Contracts with Customers. Under ASC 606, the Company recognizes revenue from the commercial sales of products, licensing agreements and contracts to perform pilot studies by applying the following steps: (1) identify the contract with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to each performance obligation in the contract; and (5) recognize revenue when each performance obligation is satisfied. Our revenue is primarily generated through our subsidiary, Digipath Labs, Inc. (“Digipath Labs”), which recognizes revenue from the analytical testing of cannabis products for licensed producers and cultivators within the state of Nevada on a determinable fixed fee per test, or panel of tests basis. Revenue from the performance of those services is recognized upon completion of the tests, at which time test results are delivered to the customer, provided collectability of the fee is reasonably assured. We typically require payment within thirty days of the delivery of results. Management estimates an allowance for doubtful accounts based on the aging of its receivables.
Discontinued Operations	Discontinued Operations On April 20, 2023, the Company and Digipath Labs entered into an Asset Purchase Agreement (the “Purchase Agreement”) with DPL NV, LLC (“Buyer”), pursuant to which Digipath Labs has agreed to sell substantially all of its assets to Buyer for a cash purchase price of $ 2,300,000 Assets and liabilities of the discontinued operations are aggregated and reported separately as assets and liabilities of discontinued operations in the Consolidated Balance Sheets as of June 30, 2023 and September 30, 2022. The results of discontinued operations are aggregated and presented separately in the Consolidated Statements of Operations as net income from discontinued operations for the periods ended June 30, 2023 and 2022. The cash flows of the discontinued operations are reflected as cash flows of discontinued operations within the Company’s Consolidated Statements of Cash Flows for the periods ended June 30, 2023 and 2022. Amounts presented in discontinued operations have been derived from our consolidated financial statements and accounting records using the historical basis of assets, liabilities, results of operations, and cash flows of Digipath Labs. The discontinued operations exclude general corporate allocations.
Stock-Based Compensation	Stock-Based Compensation The Company accounts for equity instruments issued to employees in accordance with the provisions of ASC 718 Stock Compensation (ASC 718) and Equity-Based Payments to Non-employees pursuant to ASC 2018-07 (ASC 2018-07). All transactions in which the consideration provided in exchange for the purchase of goods or services consists of the issuance of equity instruments are accounted for based on the fair value of the consideration received or the fair value of the equity instrument issued, whichever is more reliably measurable. The measurement date of the fair value of the equity instrument issued is the earlier of the date on which the counterparty’s performance is complete or the date at which a commitment for performance by the counterparty to earn the equity instruments is reached because of sufficiently large disincentives for nonperformance.
Income Taxes	Income Taxes The Company recognizes deferred tax assets and liabilities based on differences between the financial reporting and tax basis of assets and liabilities using the enacted tax rates and laws that are expected to be in effect when the differences are expected to be recovered. The Company provides a valuation allowance for deferred tax assets for which it does not consider realization of such assets to be more likely than not.
Uncertain Tax Positions	Uncertain Tax Positions In accordance with ASC 740, “Income Taxes” (“ASC 740”), the Company recognizes the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be capable of withstanding examination by the taxing authorities based on the technical merits of the position. These standards prescribe a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. These standards also provide guidance on de-recognition, classification, interest and penalties, accounting in interim periods, disclosure, and transition. Various taxing authorities periodically audit the Company’s income tax returns. These audits include questions regarding the Company’s tax filing positions, including the timing and amount of deductions and the allocation of income to various tax jurisdictions. In evaluating the exposures connected with these various tax filing positions, including state and local taxes, the Company records allowances for probable exposures. A number of years may elapse before a particular matter, for which an allowance has been established, is audited and fully resolved. The Company has not yet undergone an examination by any taxing authorities. The assessment of the Company’s tax position relies on the judgment of management to estimate the exposures associated with the Company’s various filing positions.
Basic and Diluted Loss Per Share	Basic and Diluted Loss Per Share The basic net loss per common share is computed by dividing the net loss by the weighted average number of common shares outstanding. Diluted net loss per common share is computed by dividing the net loss adjusted on an “as if converted” basis, by the weighted average number of common shares outstanding plus potential dilutive securities. For the three and nine months ended June 30, 2023 and 2022, potential dilutive securities of 96,705,198 72,520,865
Reclassifications	Reclassifications Certain reclassifications have been made to the prior period financial statements to conform to the current period presentation. These reclassifications had no effect on our previously reported results of operations or accumulated deficit.
Recently Issued Accounting Pronouncements	Recently Issued Accounting Pronouncements There are no recently issued accounting pronouncements that the Company has yet to adopt that are expected to have a material effect on its financial position, results of operations, or cash flows.

Nature of Business and Signif_3

Nature of Business and Significant Accounting Policies (Tables)	9 Months Ended
	Jun. 30, 2023
Accounting Policies [Abstract]
Schedule of Entities Under Common Control and Ownership	The accompanying consolidated financial statements include the accounts of the following entities, all of which were under common control and ownership at June 30, 2023: Schedule of Entities Under Common Control and Ownership Jurisdiction of Name of Entity Incorporation Relationship Digipath, Inc. (1) Nevada Parent Digipath Labs, Inc. Nevada Subsidiary Digipath Labs CA, Inc (2) California Subsidiary Digipath Labs S.A.S. (3) Colombia Subsidiary VSSL Enterprises, Ltd. (4) Canada Subsidiary (1) Holding company, which owns each of the wholly-owned subsidiaries. All subsidiaries shown above are wholly-owned by Digipath, Inc., the parent company. (2) Formed during the second fiscal quarter of 2021, but has not yet commenced significant operations. (3) Formed during the first fiscal quarter of 2019, but has not yet commenced significant operations. (4) Acquired on March 11, 2020.
Schedule of Correction of an Error	Schedule of Correction of an Error Consolidated Statement of Operations Line items for Q3-2022 effected by the restatement Previously Reported Correction of Error Effect of Discontinued operations Revised Professional Fees $ 635,969 $ (12,722 ) $ 1,176 $ 624,423 Total operating expenses 1,455,757 (12,722 ) (700,766 ) 742,269 Operating loss (701,704 ) 12,722 (53,287 ) (742,269 ) Net loss (1,240,654 ) 12,722 - (1,227,932 ) Deemed Dividend - (192,154 ) - (192,154 ) Net Income (loss) to common shareholders (1,240,654 ) (179,432 ) - (1,420,086 ) Consolidated Statement of Cash Flows Line items for Q3-2022 effected by the restatement Previously Reported Correction of Error Effect of Discontinued operations Revised Net Loss $ (1,240,654 ) $ 12,722 $ (40,181 ) $ (1,268,113 ) Stock-based compensation 210,449 (12,722 ) - 197,727 Non-cash Investing and Financing Activities Conversion of Series A preferred into Series B preferred 278,000 (192,154 ) - 85,846 Deemed dividend on preferred exchange 192,154 - 192,154

Fair Value of Financial Instr_2

Fair Value of Financial Instruments (Tables)	9 Months Ended
	Jun. 30, 2023
Investments, All Other Investments [Abstract]
Summary of Financial Instruments at Fair Value on Recurring Basis	The Company has certain financial instruments that must be measured under the new fair value standard. The following schedule summarizes the valuation of financial instruments at fair value on a recurring basis in the balance sheets as of June 30, 2023 and September 30, 2022, respectively: Summary of Financial Instruments at Fair Value on Recurring Basis Level 1 Level 2 Level 3 Fair Value Measurements at June 30, 2023 Level 1 Level 2 Level 3 Assets Cash $ 325,587 $ - $ - Liabilities Notes payable - 665,000 - Convertible notes payable, net of discounts of $ 72,069 - - 1,696,165 Level 1 Level 2 Level 3 Fair Value Measurements at September 30, 2022 Level 1 Level 2 Level 3 Assets Cash $ 56,168 $ - $ - Liabilities Notes payable - 665,000 - Convertible notes payable, net of discounts of $ 84,767 - - 1,683,467

Fixed Assets (Tables)

Fixed Assets (Tables)	9 Months Ended
	Jun. 30, 2023
Property, Plant and Equipment [Abstract]
Schedule of Fixed Assets	Fixed assets consist of the following at June 30, 2023 and September 30, 2022: Schedule of Fixed Assets June 30, September 30, As of June 30, September 30, 2023 2022 Lab equipment - 55,000 Fixed assets, gross - 55,000 Less: accumulated depreciation - - Total $ - $ 55,000

Notes Payable (Tables)

Notes Payable (Tables)	9 Months Ended
	Jun. 30, 2023
Notes Payable [Abstract]
Schedule of Notes Payable	Notes payable consists of the following at June 30, 2023 and September 30, 2022, respectively: Schedule of Notes Payable June 30, 2023 September 30, 2022 Notes payable - - On September 10, 2021, the Company issued a Secured Promissory note in the principal amount of $ 675,000 12 September 10, 2024 22,419.66 115,000 125,000 $ 665,000 $ 665,000 Total notes payable 665,000 665,000 Less: current maturities (665,000 ) (665,000 ) Notes payable $ - $ - The Company recorded interest expense pursuant to the stated interest rate and closing costs on the notes payable in the amount of $ 59,686 65,785 Notes payable – discontinued operations On December 26, 2019, the Company financed the purchase of $ 377,124 291,931 5.75 5,622 five-year December 26, 2024 95,987 141,348

Convertible Notes Payable (Tabl

Convertible Notes Payable (Tables)	9 Months Ended
	Jun. 30, 2023
Debt Disclosure [Abstract]
Schedule of Related Party Convertible Notes Payable	Related Party Convertible notes payable consist of the following at June 30, 2023 and September 30, 2022, respectively: Schedule of Related Party Convertible Notes Payable June 30, September 30, 2023 2022 Related party convertible notes payable $ - $ 310,272 On February 10, 2020, the Company completed the sale to an accredited investor of a 9% Secured Convertible Promissory Note in the principal amount of $ 350,000 August 10, 2022 9 0.15 0.03 50,000 400,000 50,000 1,666,667 0.03 February 11, 2024 4,550,000 43,788 $ 350,000 $ 350,000 Total related party convertible notes payable 350,000 350,000 Less: unamortized debt discounts (17,993 ) (39,728 ) Total convertible debt 332,007 310,272 Less: current maturities (332,007 ) - Related party convertible notes payable $ - $ 310,272
Schedule of Convertible Notes Payable	Convertible notes payable consist of the following at June 30, 2023 and September 30, 2022, respectively: Schedule of Convertible Notes Payable June 30, September 30, 2023 2022 Convertible notes payable $ - $ 174,726 On February 11, 2020, the Company completed the sale to an accredited investor of a 9% Secured Convertible Promissory Note in the principal amount of $ 50,000 August 11, 2022 9 0.15 0.03 10,000 60,000 10,000 333,334 0.03 February 11, 2024 650,000 6,989 $ 50,000 $ 50,000 On February 11, 2020, the Company completed the sale to an accredited investor of a 9% Secured Subordinated Convertible Promissory Note in the principal amount of $ 150,000 August 11, 2022 9 0.15 0.03 50,000 200,000 50,000 1,666,667 0.03 February 11, 2024 1,950,000 20,968 150,000 150,000 On September 23, 2019, the Company received proceeds of $ 200,000 8 August 10, 2022 0.11 August 10, 2022 0.03 90,000 3,000,000 0.03 355,469 98,188 February 11, 2024 4,621,105 32,166 355,469 355,469 On November 8, 2018, the Company received proceeds of $ 350,000 8 August 10, 2022 0.14 August 10, 2022 0.03 February 11, 2024 4,550,000 31,671 350,000 350,000 On October 1, 2022, The Company entered into a senior secured convertible note that carries an 8 February 11, 2024 362,765 0.01 4,715,945 30,102 362,765 362,765 On November 5, 2018, the Company received proceeds of $ 150,000 8 August 10, 2022 0.14 August 10, 2022 0.03 150,000 150,000 Total convertible notes payable 1,418,234 1,418,234 Less: unamortized debt discounts (54,076 ) (45,039 ) Total convertible debt 1,364,158 1,373,195 Less: current maturities (1,364,158 ) (1,198,469 ) Convertible notes payable $ - $ 174,726
Schedule of Interest Expense	The Company recognized interest expense for the nine months ended June 30, 2023 and 2022, respectively, as follows: Schedule of Interest Expense June 30, June 30, 2023 2022 Interest on notes payable 59,686 65,785 Amortization of beneficial conversion features 106,636 58,654 Interest on convertible notes 111,285 79,796 Total interest expense $ 277,607 $ 204,235

Common Stock Options (Tables)

Common Stock Options (Tables)	9 Months Ended
	Jun. 30, 2023
Share-Based Payment Arrangement [Abstract]
Summary of Common Stock Options Outstanding	The following is a summary of information about the stock options outstanding at June 30, 2023. Summary of Common Stock Options Outstanding Shares Underlying Options Outstanding Shares Underlying Options Exercisable Weighted Shares Average Weighted Shares Weighted Range of Underlying Remaining Average Underlying Average Exercise Options Contractual Exercise Options Exercise Prices Outstanding Life Price Exercisable Price $ 0.0056 0.13 8,120,000 5.28 $ 0.052 6,020,000 $ 0.069
Schedule of Weighted-Average Assumptions Used for Grants	The fair value of each option grant is estimated on the date of grant using the Black-Scholes option pricing model with the following weighted-average assumptions used for grants during the nine months ended June 30, 2023: Schedule of Weighted-Average Assumptions Used for Grants June 30, 2023 Average risk-free interest rates 3.88 % Average expected life (in years) 2.90 Volatility 184 %
Schedule of Activity of Outstanding Common Stock Options	The following is a summary of activity of outstanding common stock options: Schedule of Activity of Outstanding Common Stock Options Weighted Average Number Exercise of Shares Price Balance, September 30, 2022 6,020,000 $ 0.069 Options issued 2,100,000 0.006 Options forfeited - - Balance, June 30, 2023 8,120,000 $ 0.052 Exercisable, June 30, 2023 6,020,000 $ 0.069

Common Stock Warrants (Tables)

Common Stock Warrants (Tables)	9 Months Ended
	Jun. 30, 2023
Common Stock Warrants
Summary of Common Stock Warrants Outstanding	The following is a summary of information about our warrants to purchase common stock outstanding at June 30, 2023 (including those issued to both investors and service providers). Summary of Common Stock Warrants Outstanding Shares Underlying Shares Underlying Warrants Outstanding Warrants Exercisable Weighted Shares Average Weighted Shares Weighted Range of Underlying Remaining Average Underlying Average Exercise Warrants Contractual Exercise Warrants Exercise Prices Outstanding Life Price Exercisable Price $ 0.0074 0.10 15,387,050 9.01 $ 0.02 15,387,050 $ 0.02
Schedule of Outstanding Common Stock Warrants Activity	The following is a summary of activity of outstanding common stock warrants: Schedule of Outstanding Common Stock Warrants Activity Weighted Average Number Exercise of Shares Price Balance, September 30, 2022 1,500,000 $ 0.10 Warrants granted 13,887,050 $ 0.007 Warrants expired - - Balance, June 30, 2023 15,387,050 $ 0.016 Exercisable, June 30, 2023 15,387,050 $ 0.016

Discontinued Operations (Tables

Discontinued Operations (Tables)	9 Months Ended
	Jun. 30, 2023
Discontinued Operations and Disposal Groups [Abstract]
Schedule of Discontinued Operations Income Statement Balance Sheet and Additional Disclosures	The balance sheets of Digipath Labs are summarized below: Schedule of Discontinued Operations Income Statement Balance Sheet and Additional Disclosures June 30, 2023 September 30, 2022 Current assets: Accounts receivable, net $ 302,300 $ 335,085 Deposits 18,675 25,141 Other current assets 32,400 32,971 Total current assets 353,375 393,197 Right-of-use asset 240,602 316,961 Fixed assets, net 365,986 405,823 Total long term assets 606,588 722,784 Total Assets $ 959,963 $ 1,115,981 Current liabilities: Accounts payable $ 241,991 $ 334,909 Accrued expenses 58,439 32,571 Current portion of operating lease liabilities 110,772 100,685 Current maturities of notes payable 63,598 60,920 Total current liabilities 474,800 529,085 Operating lease liabilities 143,245 229,825 Notes payable 32,389 80,428 Total long term liabilities 175,634 310,253 Total Liabilities $ 650,434 $ 839,338 The statements of operations of Digipath Labs combined are summarized below: For the Three Months Ended For the Nine Months Ended June 30, June 30, 2023 2022 2023 2022 Revenues $ 785,224 $ 682,665 $ 2,272,689 $ 1,986,985 Cost of sales 382,655 414,299 1,265,098 1,232,932 Gross profit 402,569 268,366 1,007,591 754,053 Operating expenses: General and administrative 226,466 309,766 731,457 701,942 Professional fees 50,843 6,907 94,302 (1,176 ) Total operating expenses 277,309 316,673 825,759 700,766 Operating income(loss) 125,260 (48,307 ) 181,832 53,287 Other income (expense): Other income 322,798 - 322,798 - Interest expense (1,527 ) (4,670 ) (5,233 ) (13,106 ) Total other income (expense) 321,271 (4,670 ) 317,565 (13,106 ) Net income (loss) $ 446,531 $ (52,977 ) $ 499,397 $ 40,181

Schedule of Entities Under Comm

Schedule of Entities Under Common Control and Ownership (Details)	9 Months Ended
	Jun. 30, 2023
Entities Under Common Control and Ownership One [Member]
Name of Entity	Digipath, Inc.	[1]
Jurisdiction of Incorporation	Nevada
Relationship	Parent
Entities Under Common Control and Ownership Two [Member]
Name of Entity	Digipath Labs, Inc.
Jurisdiction of Incorporation	Nevada
Relationship	Subsidiary
Entities Under Common Control and Ownership Three [Member]
Name of Entity	Digipath Labs CA, Inc	[2]
Jurisdiction of Incorporation	California
Relationship	Subsidiary
Entities Under Common Control and Ownership Four [Member]
Name of Entity	Digipath Labs S.A.S.	[3]
Jurisdiction of Incorporation	Colombia
Relationship	Subsidiary
Entities Under Common Control and Ownership Five [Member]
Name of Entity	VSSL Enterprises, Ltd.	[4]
Jurisdiction of Incorporation	Canada
Relationship	Subsidiary
[1]Holding company, which owns each of the wholly-owned subsidiaries. All subsidiaries shown above are wholly-owned by Digipath, Inc., the parent company.[2]Formed during the second fiscal quarter of 2021, but has not yet commenced significant operations.[3]Formed during the first fiscal quarter of 2019, but has not yet commenced significant operations.[4]Acquired on March 11, 2020.

Schedule of Correction of an Er

Schedule of Correction of an Error (Details) - USD ($)	3 Months Ended						9 Months Ended
	Jun. 30, 2023	Mar. 31, 2023	Dec. 31, 2022	Jun. 30, 2022	Mar. 31, 2022	Dec. 31, 2021	Jun. 30, 2023	Jun. 30, 2022
Professional Fees	$ 86,435			$ 74,201			$ 262,072	$ 624,423
Total operating expenses	95,250			109,912			356,085	742,269
Operating loss	(95,250)			(109,912)			(356,085)	(742,269)
Net loss	293,533	$ (67,498)	$ (240,330)	(576,733)	$ (373,596)	$ (277,603)	(14,295)	(1,227,932)
Deemed Dividend								(192,154)
Net Income (loss) to common shareholders	293,533			(576,733)			(14,295)	(1,420,086)
Net Loss	$ (152,998)			$ (523,756)			(513,692)	(1,268,113)
Stock-based compensation							55,672	197,727
Non-cash Investing and Financing Activities
Conversion of Series A preferred into Series B preferred								85,846
Deemed dividend on preferred exchange								192,154
Previously Reported [Member]
Professional Fees								635,969
Total operating expenses								1,455,757
Operating loss								(701,704)
Net loss								(1,240,654)
Deemed Dividend
Net Income (loss) to common shareholders								(1,240,654)
Net Loss								(1,240,654)
Stock-based compensation								210,449
Non-cash Investing and Financing Activities
Conversion of Series A preferred into Series B preferred								278,000
Revision of Prior Period, Error Correction, Adjustment [Member]
Professional Fees								(12,722)
Total operating expenses								(12,722)
Operating loss								12,722
Net loss								12,722
Deemed Dividend								(192,154)
Net Income (loss) to common shareholders								(179,432)
Net Loss								12,722
Stock-based compensation								(12,722)
Non-cash Investing and Financing Activities
Conversion of Series A preferred into Series B preferred								(192,154)
Deemed dividend on preferred exchange								192,154
Effect Of Discontinued Operations [Member]
Professional Fees								1,176
Total operating expenses								(700,766)
Operating loss								(53,287)
Net loss
Deemed Dividend
Net Income (loss) to common shareholders
Net Loss								(40,181)
Stock-based compensation
Non-cash Investing and Financing Activities
Conversion of Series A preferred into Series B preferred
Deemed dividend on preferred exchange

Nature of Business and Signif_4

Nature of Business and Significant Accounting Policies (Details Narrative) - USD ($)		3 Months Ended		9 Months Ended
	Apr. 20, 2023	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Schedule of Equity Method Investments [Line Items]
Cash purchase price				$ 275,000	$ 175,000
Antidilutive securities		96,705,198	72,520,865	96,705,198	72,520,865
Discontinued Operations, Held-for-Sale [Member] | Purchase Agreement [Member]
Schedule of Equity Method Investments [Line Items]
Cash purchase price	$ 2,300,000

Going Concern (Details Narrativ

Going Concern (Details Narrative) - USD ($)	Jun. 30, 2023	Sep. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Working Capital	$ 2,567,011
Accumulated deficit	20,023,066	$ 20,008,771
Cash	$ 325,587	$ 56,168

Summary of Financial Instrument

Summary of Financial Instruments at Fair Value on Recurring Basis (Details) - USD ($)	Jun. 30, 2023	Sep. 30, 2022
Fair Value, Inputs, Level 1 [Member]
Platform Operator, Crypto-Asset [Line Items]
Cash	$ 325,587	$ 56,168
Notes payable
Convertible notes payable, net of discounts of $84,767
Fair Value, Inputs, Level 2 [Member]
Platform Operator, Crypto-Asset [Line Items]
Cash
Notes payable	665,000	665,000
Convertible notes payable, net of discounts of $84,767
Fair Value, Inputs, Level 3 [Member]
Platform Operator, Crypto-Asset [Line Items]
Cash
Notes payable
Convertible notes payable, net of discounts of $84,767	$ 1,696,165	$ 1,683,467

Summary of Financial Instrume_2

Summary of Financial Instruments at Fair Value on Recurring Basis (Details) (Parenthetical) - USD ($)	Jun. 30, 2023	Sep. 30, 2022
Convertible Debt [Member]
Short-Term Debt [Line Items]
Convertible notes discounts	$ 72,069	$ 84,767

Related Party Transactions (Det

Related Party Transactions (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended
	Jun. 30, 2023	Dec. 31, 2021	Jun. 30, 2023
Related Party Transaction [Line Items]
Compensation for services	$ 2,560	$ 52,500
Officer [Member]
Related Party Transaction [Line Items]
Common stock granted			3,400,000
Compensation for services			$ 24,820
Directors [Member]
Related Party Transaction [Line Items]
Common stock granted			1,400,000
Director [Member]
Related Party Transaction [Line Items]
Common stock granted			1,400,000
Compensation for services			$ 9,860
Chief Financial Officer [Member]
Related Party Transaction [Line Items]
Service for incurred fees			45,000
Service for incurred fees			111,437
Board Of Directors [Member]
Related Party Transaction [Line Items]
Service for incurred fees			47,000
Payment to directors			30,000
Payments waived off			138,000
Due to related party	5,000		5,000
Officer And Directors [Member]
Related Party Transaction [Line Items]
Reimbursable expenses	$ 2,813		$ 2,813

Note Receivable (Details Narrat

Note Receivable (Details Narrative) - USD ($)							13 Months Ended
	Mar. 31, 2024	Dec. 31, 2023	Sep. 30, 2023	Jun. 30, 2023	Jun. 30, 2023	Dec. 08, 2022	Sep. 30, 2022	Aug. 23, 2021	Jun. 13, 2019
Financing Receivable, Modified [Line Items]
Purchase price note receivable							$ 100,000
Northwest Analytical Labs, Inc. [Member] | Related Party [Member]
Financing Receivable, Modified [Line Items]
Loan received from related party									$ 95,000
Debt instrument stated percentage									10%
C3 Labs, Inc., [Member] | Related Party [Member]
Financing Receivable, Modified [Line Items]
Loan received from related party							$ 1,047,649	$ 1,047,649
Debt instrument stated percentage							8%	8%
Debt Instrument, Maturity Date							Aug. 23, 2022
Interest receivable							$ 64,017
Invictus Wealth Group [Member] | Asset Purchase Agreement [Member]
Financing Receivable, Modified [Line Items]
Debt instrument stated percentage						10%
Debt Instrument, Maturity Date						Dec. 31, 2023
Purchase price note receivable						$ 900,000
Upfront payment						275,000
Purchase price note receivable						$ 625,000
Debt final payment				$ 100,000
Received portion of upfront payment					$ 275,000
Invictus Wealth Group [Member] | Asset Purchase Agreement [Member] | Forecast [Member]
Financing Receivable, Modified [Line Items]
Debt final payment		$ 425,000	$ 100,000
Invictus Wealth Group [Member] | Asset Purchase Agreement [Member] | Forecast [Member] | Extended Maturity [Member]
Financing Receivable, Modified [Line Items]
Debt final payment	$ 425,000	$ 100,000	$ 100,000

Schedule of Fixed Assets (Detai

Schedule of Fixed Assets (Details) - USD ($)	Jun. 30, 2023	Sep. 30, 2022
Property, Plant and Equipment [Abstract]
Lab equipment		$ 55,000
Fixed assets, gross		55,000
Less: accumulated depreciation
Total		$ 55,000

Fixed Assets (Details Narrative

Fixed Assets (Details Narrative) - USD ($)	9 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Property, Plant and Equipment [Abstract]
Impairment expense	$ 55,000

Schedule of Notes Payable (Deta

Schedule of Notes Payable (Details) - USD ($)	Jun. 30, 2023	Sep. 30, 2022
Short-Term Debt [Line Items]
Notes payable
Total notes payable	665,000	665,000
Less: current maturities	(665,000)	(665,000)
Notes payable
Notes Payable [Member]
Short-Term Debt [Line Items]
Total notes payable	665,000	665,000
Notes Payable [Member] | Discontinued Operations [Member]
Short-Term Debt [Line Items]
Total notes payable	$ 95,987	$ 141,348

Schedule of Notes Payable (De_2

Schedule of Notes Payable (Details) (Parenthetical) - USD ($)			12 Months Ended
	Sep. 10, 2021	Dec. 26, 2019	Sep. 30, 2022
Canna Lab Note [Member]
Short-Term Debt [Line Items]
Principal amount	$ 675,000
Debt instrument stated percentage	12%
Debt instrument, maturity date	Sep. 10, 2024
Debt instrument periodic payment	$ 22,419.66
Secured Promissory Note [Member]
Short-Term Debt [Line Items]
Debt conversion original debt amount			$ 115,000
Repayments of notes payable			$ 125,000
Note Payable [Member] | Discontinued Operations [Member]
Short-Term Debt [Line Items]
Debt instrument stated percentage		5.75%
Debt instrument, maturity date		Dec. 26, 2024
Debt instrument periodic payment		$ 5,622
Payments for lab equipment		377,124
Proceeds from bank loan		$ 291,931
Debt instrument term description		5 years

Notes Payable (Details Narrativ

Notes Payable (Details Narrative) - USD ($)	9 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Note Payable [Member]
Short-Term Debt [Line Items]
Interest expense	$ 59,686	$ 65,785

Schedule of Related Party Conve

Schedule of Related Party Convertible Notes Payable (Details) - USD ($)	Jun. 30, 2023	Sep. 30, 2022
Short-Term Debt [Line Items]
Total related party convertible notes payable	$ 1,418,234	$ 1,418,234
Total convertible debt	1,364,158	1,373,195
Less: current maturities	(1,364,158)	(1,198,469)
Convertible Notes Payable [Member]
Short-Term Debt [Line Items]
Less: unamortized debt discounts	(72,069)
Related Party [Member]
Short-Term Debt [Line Items]
Related party convertible notes payable		310,272
Total related party convertible notes payable	350,000	350,000
Less: unamortized debt discounts	(17,993)	(39,728)
Total convertible debt	332,007	310,272
Less: current maturities	(332,007)
Related Party [Member] | Convertible Notes Payable [Member]
Short-Term Debt [Line Items]
Total related party convertible notes payable	$ 350,000	$ 350,000

Schedule of Related Party Con_2

Schedule of Related Party Convertible Notes Payable (Details) (Parenthetical) - USD ($)					9 Months Ended
	Aug. 08, 2022	Dec. 29, 2020	Dec. 28, 2020	Feb. 11, 2020	Jun. 30, 2023	Jun. 30, 2022
Short-Term Debt [Line Items]
Proceeds from convertible debt						$ 402,765
Secured Subordinated Convertible Promissory Note [Member] | Accredited Investors [Member]
Short-Term Debt [Line Items]
Principal amount		$ 50,000	$ 400,000	$ 350,000
Maturity date	Feb. 11, 2024			Aug. 10, 2022
Debt instrument interest percentage				9%
Conversion price		$ 0.03	$ 0.03	$ 0.15
Proceeds from convertible debt			$ 50,000
Debt converted principal value, shares		1,666,667
Shares of common stock issued	4,550,000
Debt instrument fair value	$ 43,788

Schedule of Convertible Notes P

Schedule of Convertible Notes Payable (Details) - USD ($)	Jun. 30, 2023	Sep. 30, 2022
Short-Term Debt [Line Items]
Total convertible notes payable	$ 1,418,234	$ 1,418,234
Less: unamortized debt discounts	(54,076)	(45,039)
Total convertible debt	1,364,158	1,373,195
Less: current maturities	(1,364,158)	(1,198,469)
Convertible Notes Payable One [Member]
Short-Term Debt [Line Items]
Total convertible notes payable	50,000	50,000
Convertible Notes Payable Two [Member]
Short-Term Debt [Line Items]
Total convertible notes payable	150,000	150,000
Convertible Notes Payable Three [Member]
Short-Term Debt [Line Items]
Total convertible notes payable	355,469	355,469
Convertible Notes Payable Four [Member]
Short-Term Debt [Line Items]
Total convertible notes payable	350,000	350,000
Convertible Notes Payable Five [Member]
Short-Term Debt [Line Items]
Total convertible notes payable	362,765	362,765
Convertible Notes Payable Six [Member]
Short-Term Debt [Line Items]
Total convertible notes payable	150,000	150,000
Nonrelated Party [Member]
Short-Term Debt [Line Items]
Convertible notes payable		$ 174,726

Schedule of Convertible Notes_2

Schedule of Convertible Notes Payable (Details) (Parenthetical) - USD ($)

9 Months Ended

12 Months Ended

Oct. 02, 2022

Aug. 08, 2022

Sep. 30, 2021

Feb. 22, 2021

Dec. 29, 2020

Dec. 28, 2020

Sep. 30, 2020

Feb. 11, 2020

Sep. 23, 2019

Nov. 08, 2018

Nov. 05, 2018

Jun. 30, 2023

Jun. 30, 2022

Sep. 30, 2022

Short-Term Debt [Line Items]

Proceeds from convertible debt

$ 402,765

Amortization of debt discount premium

$ 106,636

$ 58,654

Debt instrument purchase of warrant

15,387,050

9% Secured Convertible Promissory Note [Member] | Accredited Investors [Member]

Short-Term Debt [Line Items]

Principal amount

$ 10,000

$ 60,000

$ 50,000

Maturity date

Feb. 11, 2024

Aug. 11, 2022

Debt instrument interest percentage

9%

Conversion price

$ 0.03

$ 0.03

$ 0.15

Proceeds from convertible debt

$ 10,000

Debt converted principal value, shares

333,334

Shares issued

650,000

Debt instrument fair value

$ 6,989

9% Secured Subordinated Convertible Promissory Note [Member] | Accredited Investors [Member]

Short-Term Debt [Line Items]

Principal amount

$ 200,000

$ 150,000

Maturity date

Feb. 11, 2024

Aug. 11, 2022

Debt instrument interest percentage

9%

Conversion price

$ 0.03

$ 0.03

$ 0.15

Proceeds from convertible debt

$ 50,000

Debt converted principal value, shares

1,666,667

Debt converted principal amount

$ 50,000

9% Secured Subordinated Convertible Promissory Note [Member] | Accredited Investors One [Member]

Short-Term Debt [Line Items]

Shares issued

1,950,000

Debt instrument fair value

$ 20,968

Senior Secured Convertible Note [Member]

Short-Term Debt [Line Items]

Maturity date

Feb. 11, 2024

Aug. 10, 2022

Aug. 10, 2022

Debt instrument interest percentage

8%

Conversion price

$ 0.03

$ 0.03

$ 0.11

Proceeds from convertible debt

$ 200,000

Debt converted principal value, shares

3,000,000

Debt converted principal amount

$ 90,000

Debt instrument periodic payment

$ 355,469

Amortization of debt discount premium

$ 98,188

Debt instrument purchase of warrant

4,621,105

Debt instrument fair value of warrant

$ 32,166

Senior Secured Convertible Note One [Member]

Short-Term Debt [Line Items]

Maturity date

Feb. 11, 2024

Aug. 10, 2022

Aug. 10, 2022

Debt instrument interest percentage

8%

Conversion price

$ 0.03

$ 0.14

Proceeds from convertible debt

$ 350,000

Debt instrument purchase of warrant

4,550,000

Debt instrument fair value of warrant

$ 31,671

Senior Secured Convertible Note Two [Member]

Short-Term Debt [Line Items]

Maturity date

Feb. 11, 2024

Debt instrument interest percentage

8%

Conversion price

$ 0.01

Debt instrument purchase of warrant

4,715,945

Debt instrument fair value of warrant

$ 30,102

Debt conversion original debt amount

$ 362,765

Senior Secured Convertible Note Three [Member]

Short-Term Debt [Line Items]

Maturity date

Aug. 10, 2022

Aug. 10, 2022

Debt instrument interest percentage

8%

Conversion price

$ 0.03

$ 0.14

Proceeds from convertible debt

$ 150,000

Schedule of Interest Expense (D

Schedule of Interest Expense (Details) - USD ($)	9 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Debt Disclosure [Abstract]
Interest on notes payable	$ 59,686	$ 65,785
Amortization of beneficial conversion features	106,636	58,654
Interest on convertible notes	111,285	79,796
Total interest expense	$ 277,607	$ 204,235

Convertible Notes Payable (Deta

Convertible Notes Payable (Details Narrative) - USD ($)	9 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Short-Term Debt [Line Items]
Amortization of debt discounts	$ 106,636	$ 58,654
Maximum Share Amount [Member]
Short-Term Debt [Line Items]
Maximum amount owned percentage of issued and outstanding common shares	4.99%
Convertible Notes Payable [Member]
Short-Term Debt [Line Items]
Debt discount conversion feature of convertible debt	$ 93,938
Amortization of debt discounts	106,636	58,654
Unamortized discounts	72,069
Convertible notes interest expense	$ 111,285	$ 79,796

Stockholders_ Equity (Details N

Stockholders’ Equity (Details Narrative) - USD ($)		3 Months Ended				9 Months Ended
	Mar. 02, 2023	Jun. 30, 2023	Mar. 31, 2023	Dec. 31, 2022	Dec. 31, 2021	Jun. 30, 2023	Sep. 30, 2022
Class of Stock [Line Items]
Preferred stock, shares authorized		10,000,000				10,000,000
Preferred stock, par value		$ 0.001				$ 0.001
Stock repurchased, value			$ 100
Common stock par value		$ 0.001				$ 0.001	$ 0.001
Common stock authorized		250,000,000				250,000,000	250,000,000
Common stock, shares issued		87,096,820				87,096,820	75,146,820
Common stock, shares outstanding		87,096,820				87,096,820	75,146,820
Issuance of common shares to settle stock payable
Compensation for services		$ 2,560			$ 52,500
Officer [Member]
Class of Stock [Line Items]
Common stock granted						3,400,000
Compensation for services						$ 24,820
Director [Member]
Class of Stock [Line Items]
Common stock granted						1,400,000
Compensation for services						$ 9,860
Series A Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, shares authorized		6,000,000				6,000,000	6,000,000
Preferred stock, par value		$ 0.001				$ 0.001	$ 0.001
Preferred stock, shares issued		1,047,942				1,047,942	1,047,942
Preferred stock, shares outstanding		1,047,942				1,047,942	1,047,942
Series B Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Temporary equity, shares authorized		1,500,000				1,500,000	1,500,000
Temporary equity, shares issued		333,600				333,600	333,600
Temporary equity, shares outstanding		333,600				333,600	333,600
Series C Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, shares authorized		1,000				1,000
Preferred stock, shares designated remaining		2,499,000				2,499,000
Preferred stock voting rights						the Company’s common stock on all matters presented to the holders of common stock, whether at a special or annual meeting, by written action in lieu of a meeting or otherwise, on the basis of 200,000 votes for each share of Series C Preferred Stock.
Preferred stock voting rights		$ 0.10				$ 0.10
Conversion of stock description						Upon the liquidation or dissolution of the Company, or any merger or sale of all or substantially all of the assets, or upon a change in control whereby a stockholder gains control of 50% or more of the outstanding shares of common stock, the shares of Series C Preferred are entitled to receive, prior to any distribution to the holders of common stock, 100% of the stated value per share of Series C Preferred.
Stock repurchased, value	$ 100
Series C Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, shares authorized		1,000				1,000	1,000
Preferred stock, par value		$ 0.001				$ 0.001	$ 0.001
Preferred stock, shares issued		0				0	1,000
Preferred stock, shares outstanding		0				0	1,000
Series A Preferred Stock [Member]
Class of Stock [Line Items]
Conversion of stock, shares converted						1,047,942
Convertible shares		5,239,710				5,239,710
Common stock, terms of conversion						No holder is permitted to convert its shares of Series A Preferred if such conversion would cause the holder to beneficially own more than 4.99% of the issued and outstanding common stock of the Company immediately after such conversion, unless waived by such holder by providing at least sixty-five days’ notice.
Percentage of distribution on purchase price		100%				100%
Series A Preferred Stock [Member] | Noteholders [Member]
Class of Stock [Line Items]
Percentage of equity beneficial ownership		4.99%				4.99%
Common Stock [Member]
Class of Stock [Line Items]
Issuance of common shares to settle stock payable, shares						7,150,000
Issuance of common shares to settle stock payable						$ 71,745

Mezzanine Equity (Details Narra

Mezzanine Equity (Details Narrative)	9 Months Ended
	Jun. 30, 2023 $ / shares shares
Preferred stock, par value	$ 0.001
Conversion of stock shares issued | shares	8,340,000
Series B Preferred Stock [Member]
Preferred stock, par value	$ 1
Conversion price	$ 0.04
Conversion shares converted | shares	333,600
Common stock, terms of conversion	No holder is permitted to convert its shares of Series B Preferred if such conversion would cause the holder to beneficially own more than 4.99% of the issued and outstanding common stock of the Company immediately after such conversion, unless waived by such holder by providing at least sixty-five days’ notice.
Conversion of stock description	Upon the liquidation or dissolution of the Company, or any merger or sale of all or substantially all of the assets, or upon a change in control whereby a stockholder gains control of 50% or more of the outstanding shares of common stock, the shares of Series B Preferred are entitled to receive, prior to any distribution to the holders of common stock, 100% of the purchase price per share of Series B Preferred plus all accrued but unpaid dividends.

Summary of Common Stock Options

Summary of Common Stock Options Outstanding (Details)	9 Months Ended
	Jun. 30, 2023 $ / shares shares
Share-Based Payment Arrangement [Abstract]
Range of Exercise Price, Minimum	$ 0.0056
Range of Exercise Price, Maximum	$ 0.13
Number of Options Outstanding | shares	8,120,000
Weighted Average Remaining Contractual Life	5 years 3 months 10 days
Weighted Average Exercise Price	$ 0.052
Number of Shares Exercisable | shares	6,020,000
Weighted Average Exercise Price Exercisable	$ 0.069

Schedule of Weighted-Average As

Schedule of Weighted-Average Assumptions Used for Grants (Details)	9 Months Ended
	Jun. 30, 2023
Share-Based Payment Arrangement [Abstract]
Average risk-free interest rates	3.88%
Average expected life	2 years 10 months 24 days
Volatility	184%

Schedule of Activity of Outstan

Schedule of Activity of Outstanding Common Stock Options (Details)	9 Months Ended
	Jun. 30, 2023 $ / shares shares
Share-Based Payment Arrangement [Abstract]
Number of Shares Outstanding, Beginning balance | shares	6,020,000
Weighted Average Exercise Price, Outstanding, Beginning | $ / shares	$ 0.069
Number of Shares Options issued | shares	2,100,000
Weighted Average Exercise Price, Options issued | $ / shares	$ 0.006
Number of Shares Options forfeited | shares
Weighted Average Exercise Price, Options Forfeited | $ / shares
Number of Shares Outstanding, Ending balance | shares	8,120,000
Weighted Average Exercise Price, Outstanding, Ending | $ / shares	$ 0.052
Number of Shares Exercisable | shares	6,020,000
Weighted Average Exercise Price, Exercisable | $ / shares	$ 0.069

Common Stock Options (Details N

Common Stock Options (Details Narrative) - USD ($)		9 Months Ended
	Jun. 21, 2016	Jun. 30, 2023	Jun. 30, 2022
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Volatility rate		184%
Expected term		2 years 10 months 24 days
Weighted average fair value of options granted with exercise price		$ 0.006
Intrinsic value , outstanding		$ 3,150
Intrinsic value , exercisable		$ 0
Market price, per share		$ 0.007
Share-Based Payment Arrangement, Option [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Weighted average fair value of options granted with exercise price		$ 0.006
Amortization of Stock Option [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Stock-based compensation expenses		$ 20,992	$ 66,949
Unamortized expenses expected to be expensed		$ 4,643
2012 Stock Incentive Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Volatility rate		184%
Call option values price		$ 0.00497
Exercise prices		$ 0.0056
Expected term		5 years 9 months
2012 Stock Incentive Plan [Member] | Common Stock [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Shares issued to certain employees		2,100,000
Total fair value		$ 10,446
2012 Stock Incentive Plan [Member] | Maximum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of shares issued under stock plan	11,500,000

Summary of Common Stock Warrant

Summary of Common Stock Warrants Outstanding (Details)	9 Months Ended
	Jun. 30, 2023 $ / shares shares
Common Stock Warrants
Range of Exercise Price, Minimum	$ 0.0074
Range of Exercise Price, Minimum	$ 0.10
Number of Warrants Outstanding | shares	15,387,050
Weighted Average Remaining Contractual Life	9 years 3 days
Weighted Average Exercise Price	$ 0.02
Number of Warrants Exercisable | shares	15,387,050
Weighted Average Exercise Price, Exercisable	$ 0.02

Schedule of Outstanding Common

Schedule of Outstanding Common Stock Warrants Activity (Details)	9 Months Ended
	Jun. 30, 2023 $ / shares shares
Common Stock Warrants
Number of Shares, Balance beginning | shares	1,500,000
Weighted Average Exercise Price, Balance beginning	$ 0.10
Number of Shares, Warrants granted | shares	13,887,050
Weighted Average Exercise Price, Warrants granted	$ 0.007
Number of Shares, Warrants expired | shares
Weighted Average Exercise Price, Warrants expired
Number of Shares, Balance ending | shares	15,387,050
Weighted Average Exercise Price, Balance, ending	$ 0.016
Weighted Average Exercise Price, Balance, ending	15,387,050
Weighted Average Exercise Price, Exercisable	$ 0.016

Common Stock Warrants (Details

Common Stock Warrants (Details Narrative)	9 Months Ended
	Jun. 30, 2023 USD ($) $ / shares shares
Number of warrant to purchase of common stock shares | shares	15,387,050
Warrant [Member]
Warrants, intrinic value | $	$ 0
Intrinsic value, market price per share | $ / shares	$ 0.007

Schedule of Discontinued Operat

Schedule of Discontinued Operations Income Statement Balance Sheet and Additional Disclosures (Details) - USD ($)	3 Months Ended		9 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022	Sep. 30, 2022
Current assets:
Accounts receivable, net	$ 302,300		$ 302,300		$ 335,085
Deposits	18,675		18,675		25,141
Other current assets	32,400		32,400		32,971
Total current assets	353,375		353,375		393,197
Right-of-use asset	240,602		240,602		316,961
Fixed assets, net	365,986		365,986		405,823
Total long term assets	606,588		606,588		722,784
Total Assets	959,963		959,963		1,115,981
Current liabilities:
Accounts payable	241,991		241,991		334,909
Accrued expenses	58,439		58,439		32,571
Current portion of operating lease liabilities	110,772		110,772		100,685
Current maturities of notes payable	63,598		63,598		60,920
Total current liabilities	474,800		474,800		529,085
Operating lease liabilities	143,245		143,245		229,825
Notes payable	32,389		32,389		80,428
Total long term liabilities	175,634		175,634		310,253
Total Liabilities	650,434		650,434		$ 839,338
Revenues	785,224	$ 682,665	2,272,689	$ 1,986,985
Cost of sales	382,655	414,299	1,265,098	1,232,932
Gross profit	402,569	268,366	1,007,591	754,053
Operating expenses:
General and administrative	226,466	309,766	731,457	701,942
Professional fees	50,843	6,907	94,302	(1,176)
Total operating expenses	277,309	316,673	825,759	700,766
Operating income(loss)	125,260	(48,307)	181,832	53,287
Other income (expense):
Other income	322,798		322,798
Interest expense	(1,527)	(4,670)	(5,233)	(13,106)
Total other income (expense)	321,271	(4,670)	317,565	(13,106)
Net income (loss)	$ 446,531	$ (52,977)	$ 499,397	$ 40,181

Discontinued Operations (Detail

Discontinued Operations (Details Narrative) - USD ($)		9 Months Ended
	Apr. 20, 2023	Jun. 30, 2023	Jun. 30, 2022	Apr. 20, 2022
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Cash purchase price		$ 275,000	$ 175,000
Working capital		$ (2,567,011)
Deposits				$ 230,000
Purchase Agreement [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Working capital	$ 150,000
Discontinued Operations, Held-for-Sale [Member] | Purchase Agreement [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Cash purchase price	$ 2,300,000